Literature DB >> 7704845

Antiproliferation and colony-forming inhibition activities of recombinant feline interferon (rFeIFN) on various cells in vitro.

B P Priosoeryanto1, S Tateyama, R Yamaguchi, K Uchida.   

Abstract

The antiproliferative and colony inhibiting activities of recombinant feline interferon (rFeIFN Type I) against various cells in vitro were examined. Feline and canine cells were both sensitive to rFeIFN. To inhibit the growth of feline cells by 50% approximately 5 x 10(2) to 1 x 10(3) U/mL rFeIFN was required and maximum activity was achieved at a concentration of 1 x 10(5) U/mL. Approximately 5 x 10(3) to 5 x 10(4) U/mL rFeIFN was necessary to inhibit the growth of canine cells by 50%. The antiproliferative and colony inhibiting activities of rFeIFN on canine cells appeared to be cell-specific and dose-dependent. However, human, monkey and hamster cells were resistant to rFeIFN. We suggest that rFeIFN might be useful for treatment of feline and some canine neoplastic conditions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7704845      PMCID: PMC1263736     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  21 in total

1.  Animal models for investigating antitumor effects of interferon.

Authors:  F R Balkwill
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

2.  Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro.

Authors:  E C Borden; D S Groveman; T Nasu; C Reznikoff; G T Bryan
Journal:  J Urol       Date:  1984-10       Impact factor: 7.450

3.  Intratumor administration of beta-interferon in recurrent malignant gliomas. A phase I clinical and laboratory study.

Authors:  M R Fetell; E M Housepian; M W Oster; D N Cote; M B Sisti; S G Marcus; P B Fisher
Journal:  Cancer       Date:  1990-01-01       Impact factor: 6.860

4.  Antitumor effect of human fibroblast interferon on the growth of human melanoma cells implanted in nude mice.

Authors:  N Ida; N Uenishi; A Kajita; Y Satoh
Journal:  Gan       Date:  1982-12

5.  Effects of human fibroblast interferon on human tumors transplanted into nude mice: sensitivity of human tumors to interferon.

Authors:  M Kohno; N Ida; S Nagao; N Tanaka; F Sekiguchi; N Uenishi; A Kajita; H Ogawa
Journal:  Gan       Date:  1982-12

6.  Effect of fibroblast, lymphoid, and myeloid interferons on human tumor colony formation in vitro.

Authors:  E C Bradley; F W Ruscetti
Journal:  Cancer Res       Date:  1981-01       Impact factor: 12.701

7.  Characteristics of in vitro antiproliferation activity of human interferon-beta.

Authors:  T Kataoka; F Oh-hashi; Y Sakurai; N Ida
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Antitumoral activity of human fibroblast interferon administered intranodularly.

Authors:  R Rosso; M T Nobile; M R Sertoli; A Giannitelli; P L Santi; R Volpe; G Nicolò
Journal:  Oncology       Date:  1985       Impact factor: 2.935

9.  Susceptibility of feline herpesvirus 1 and a feline calicivirus to feline interferon and recombinant human leukocyte interferons.

Authors:  R W Fulton; L J Burge
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

10.  Pharmacokinetics and toxicity of inhaled human natural interferon-beta in patients with lung cancer.

Authors:  M Halme; P Maasilta; K Mattson; K Cantell
Journal:  Respiration       Date:  1994       Impact factor: 3.580

View more
  2 in total

1.  In vitro antiproliferation activity of Typhonium flagelliforme leaves ethanol extract and its combination with canine interferons on several tumor-derived cell lines.

Authors:  Bambang Pontjo Priosoeryanto; Riski Rostantinata; Eva Harlina; Waras Nurcholis; Rachmi Ridho; Lina Noviyanti Sutardi
Journal:  Vet World       Date:  2020-05-19

2.  Adjuvant immunotherapy of feline fibrosarcoma with recombinant feline interferon-omega.

Authors:  Verena Hampel; Bianca Schwarz; Christine Kempf; Roberto Köstlin; Ulrike Schillinger; Helmut Küchenhoff; Nora Fenske; Thomas Brill; Johannes Hirschberger
Journal:  J Vet Intern Med       Date:  2007 Nov-Dec       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.